Literature DB >> 16236966

Hepatitis C virus and the lung: implications for therapy.

Jonathan Moorman1, Mustafa Saad, Semaan Kosseifi, Guha Krishnaswamy.   

Abstract

Hepatitis C virus (HCV) infection is a chronic blood-borne disease that affects > 4,000,000 individuals in the United States. The majority of individuals with HVC infection acquire a chronic hepatitis that predisposes them to the complications of cirrhosis and hepatoma. Chronic HCV infection is, however, associated with multiple extrahepatic manifestations as well, including recently recognized effects on the lung. These include primary effects on lung function, as well as secondary effects in the settings of progressive liver disease and drug treatment for HCV. In this article, we discuss the emerging clinical data that support a role for HCV infection in lung disease, describe the multiple pulmonary manifestations of this viral infection, and outline the therapies available for specific pulmonary complications of chronic HCV infection.

Entities:  

Mesh:

Year:  2005        PMID: 16236966     DOI: 10.1378/chest.128.4.2882

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  16 in total

1.  Brief Report: Coordinated Modulation of Circulating miR-21 in HIV, HIV-Associated Pulmonary Arterial Hypertension, and HIV/Hepatitis C Virus Coinfection.

Authors:  Victoria N Parikh; Joseph Park; Ivana Nikolic; Richard Channick; Paul B Yu; Teresa De Marco; Priscilla Y Hsue; Stephen Y Chan
Journal:  J Acquir Immune Defic Syndr       Date:  2015-11-01       Impact factor: 3.731

Review 2.  Pathology of pulmonary hypertension.

Authors:  Rubin M Tuder; John C Marecki; Amy Richter; Iwona Fijalkowska; Sonia Flores
Journal:  Clin Chest Med       Date:  2007-03       Impact factor: 2.878

3.  Risk of Complications After THA Increases Among Patients Who Are Coinfected With HIV and Hepatitis C.

Authors:  Siddharth A Mahure; Joseph A Bosco; James D Slover; Jonathan Vigdorchik; Richard Iorio; Ran Schwarzkopf
Journal:  Clin Orthop Relat Res       Date:  2018-02       Impact factor: 4.176

4.  Risk of echocardiographic pulmonary hypertension in individuals with human immunodeficiency virus-hepatitis C virus coinfection.

Authors:  Rohit B Sangal; Lynn E Taylor; Fizza Gillani; Athena Poppas; James R Klinger; Corey E Ventetuolo
Journal:  Ann Am Thorac Soc       Date:  2014-12

5.  Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 2 or 3.

Authors:  David R Nelson; Yves Benhamou; Wan-Long Chuang; Eric J Lawitz; Maribel Rodriguez-Torres; Robert Flisiak; Jens W F Rasenack; Wiesław Kryczka; Chuan-Mo Lee; Vincent G Bain; Stephen Pianko; Keyur Patel; Patrick W Cronin; Erik Pulkstenis; G Mani Subramanian; John G McHutchison
Journal:  Gastroenterology       Date:  2010-07-01       Impact factor: 22.682

6.  Drug-induced lung injury associated with sorafenib: analysis of all-patient post-marketing surveillance in Japan.

Authors:  Yuka Horiuchi-Yamamoto; Akihiko Gemma; Hiroyuki Taniguchi; Yoshikazu Inoue; Fumikazu Sakai; Takeshi Johkoh; Kiminori Fujimoto; Shoji Kudoh
Journal:  Int J Clin Oncol       Date:  2012-06-30       Impact factor: 3.402

Review 7.  Genomics of pulmonary arterial hypertension: implications for therapy.

Authors:  Mark W Geraci; Todd M Bull; Rubin M Tuder
Journal:  Heart Fail Clin       Date:  2010-01       Impact factor: 3.179

8.  Hepatitis C virus infection is not an independent risk factor for obstructive lung disease.

Authors:  William A Fischer; Michael B Drummond; Christian A Merlo; David L Thomas; Robert Brown; Shruti H Mehta; Robert A Wise; Greg D Kirk
Journal:  COPD       Date:  2013-07-17       Impact factor: 2.409

Review 9.  Complement and viral pathogenesis.

Authors:  Kristina A Stoermer; Thomas E Morrison
Journal:  Virology       Date:  2011-02-02       Impact factor: 3.616

10.  Venous outflow obstruction and portopulmonary hypertension after orthotopic liver transplantation.

Authors:  Guadalupe Aguirre-Avalos; Marco Antonio Covarrubias-Velasco; Antonio Gerardo Rojas-Sánchez
Journal:  Am J Case Rep       Date:  2013-09-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.